TEL AVIV, Israel, Jan. 27, 2022 /PRNewswire/ -- SciSparc Ltd.
(NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company
focusing on the development of therapies to treat disorders of the
central nervous system (the "Company"), announced that its board of
directors (the "Board") resolved to appoint Mr. Oz Adler as the
Chief Executive Officer, Mr. Itschak
Shrem as the President of the Company and Mr. Amitay Weiss as the chairman of the Board of
Directors of the Company, effective January
10, 2022. Mr. Adler will continue to serve as the Company's
Chief Financial Officer until the recruit of a suitable
replacement.
Mr. Adler joined the Company in September
2017, and since April 2018 has
served as the Company's Chief Financial Officer. Mr. Adler has a
wide variety of managerial, financial, tax and accounting
experience. Prior to joining the Company, Mr. Adler was employed as
a CPA at Kost Forer Gabbay & Kasierer, a member of Ernst &
Young Global. Mr. Adler holds a B.A. in Accounting and Business
Management from The College of Management, Israel.
Mr. Weiss has served as SciSparc's Chief Executive Officer and
on its Board of Directors since August
2020. Prior to joining the Company, Mr. Weiss held several
positions at Bank Poalei Agudat Israel Ltd., most recently as Vice
President of Business Marketing & Development. He currently
chairs and serves as director on the boards of several public
companies. Mr. Weiss earned his B.A. in Economics from New England College, and his M.B.A. and LL.B from
Ono Academic College in Israel – a
branch of the University of Manchester.
Mr. Shrem has served as the Company's Chairman of the Board of
Directors since August 2020 and
brings more than 40 years of experience in financial markets and
venture capital. Mr. Shrem will remain a board member of the
Company in addition to his new role as president.
About SciSparc (NASDAQ: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. Our focus is on creating and enhancing a portfolio of
technologies and assets based on cannabinoid pharmaceuticals. With
this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive
cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome,
for the treatment of obstructive sleep apnea and Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and
epilepsy.
Logo
- https://mma.prnewswire.com/media/1434686/SciSparc_Ltd_Logo.jpg
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
View original
content:https://www.prnewswire.com/news-releases/scisparc-presents-new-leadership-lineup-301469713.html
SOURCE SciSparc Ltd.